¼¼°èÀÇ ´ëµ¿¸Æ·ù ½ÃÀå
Aortic Aneurysm
»óǰÄÚµå : 1777788
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 467 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,228,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,684,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ëµ¿¸Æ·ù ½ÃÀåÀº 2030³â±îÁö 101¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 56¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´ëµ¿¸Æ·ù ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 10.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 101¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÈäºÎ ´ëµ¿¸Æ·ù´Â CAGR 11.7%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 72¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º¹ºÎ ´ëµ¿¸Æ·ù ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 15¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR14.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ëµ¿¸Æ·ù ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 21¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 14.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 7.4%¿Í 9.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ´ëµ¿¸Æ·ù ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ëµ¿¸Æ·ù°¡ ½ÉÇ÷°ü¿¡ ½É°¢ÇÑ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

´ëµ¿¸Æ·ù´Â ½Åü¿¡¼­ °¡Àå Å« Ç÷°üÀÎ ´ëµ¿¸ÆÀÌ ºñÁ¤»óÀûÀ¸·Î È®ÀåµÇ°Å³ª ºÎÇ®¾î ¿À¸£´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â »ý¸íÀ» À§ÇùÇÏ´Â Ç÷°ü ÁúȯÀÔ´Ï´Ù. ´ëµ¿¸Æ·ù¸¦ Ä¡·áÇÏÁö ¾Ê°í ¹æÄ¡ÇÏ¸é ÆÄ¿­µÇ¾î ½É°¢ÇÑ ³»ÃâÇ÷À» ÀÏÀ¸ÄÑ »ç¸Á¿¡ À̸¦ À§ÇèÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÌ ÁúȯÀº ÁÖ·Î º¹ºÎ ´ëµ¿¸Æ·ù(AAA)¿Í ÈäºÎ ´ëµ¿¸Æ·ù(TAA)ÀÇ µÎ °¡Áö·Î ºÐ·ùµÇ¸ç, ƯÈ÷ °í·ÉÃþ¿¡¼­´Â AAA°¡ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. °íÇ÷¾Ð, Èí¿¬, °íÄÝ·¹½ºÅ×·Ñ, À¯ÀüÀû ¼ÒÀÎ µîÀÌ ´ëµ¿¸Æ·ù ¹ß»ý¿¡ Å©°Ô ±â¿©ÇÕ´Ï´Ù. ÁÂ½Ä »ýȰ½À°ü, ºñ¸¸, ´ç´¢º´ Áõ°¡´Â Àü ¼¼°èÀûÀ¸·Î ´ëµ¿¸Æ·ù À¯º´·üÀ» ´õ¿í ¾ÇÈ­½Ã۰í ÀÖ½À´Ï´Ù. ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ Ç÷°üÁ¶¿µ¼ú(CTA), ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú(MRA), ÃÊÀ½ÆÄ µî ¿µ»óÁø´ÜÀÇ ¹ßÀüÀ¸·Î Á¶±â ¹ß°ßÀ²ÀÌ Å©°Ô Çâ»óµÇ¾î Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª Ãʱ⿡´Â ¹«Áõ»óÀ̱⠶§¹®¿¡ °íÀ§Ç豺¿¡¼­´Â ¼±º°°Ë»ç ÇÁ·Î±×·¥ÀÌ Áß¿äÇÕ´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ƯÈ÷ 65¼¼ ÀÌ»ó ³²¼ºÀ̳ª µ¿¸Æ·ù °¡Á··ÂÀÌ ÀÖ´Â »ç¶÷ µî À§Çè¿¡ óÇÑ »ç¶÷µé¿¡ ´ëÇÑ ÀÎ½Ä °³¼± Ä·ÆäÀΰú Á¤±â °ËÁø¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü Áúȯ(CVDs)ÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ëµ¿¸Æ·ù °ü¸®´Â Çö´ë ¼øÈ¯±âÇÐÀÇ ÃÖÀü¼±¿¡ À§Ä¡Çϰí ÀÖÀ¸¸ç, Á¶±â ¹ß°ß, ¸ð´ÏÅ͸µ ¹× Ä¡·áÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ´ëµ¿¸Æ·ù Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

ÀÇ·á±â¼úÀÇ Çõ½ÅÀº ´ëµ¿¸Æ·ù Áø´Ü, ¸ð´ÏÅ͸µ, Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ È¯ÀÚ ¿¹ÈÄ °³¼±°ú »ç¸Á·ü °¨¼Ò·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸î ³â µ¿¾È °¡Àå Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â Ç÷°ü ³» µ¿¸Æ·ù Ä¡·á¼ú(EVAR)°ú ÈäºÎ Ç÷°ü ³» µ¿¸Æ·ù Ä¡·á¼ú(TEVAR)ÀÌ ³Î¸® äÅÃµÇ¾î ±âÁ¸ÀÇ °³º¹ ¼ö¼úÀ» Å©°Ô ´ëüÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àúħ½ÀÀû ½Ã¼úÀº ´ëµ¿¸Æ ³»¿¡ ½ºÅÙÆ® ±×¶óÇÁÆ®¸¦ »ðÀÔÇÏ¿© ¾àÇØÁø Ç÷°üº®À» º¸°­ÇÏ´Â °ÍÀ¸·Î, ȸº¹½Ã°£, ÀÔ¿ø±â°£, ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ½Ã¼úÀÇ Çõ½Å°ú ´õºÒ¾î ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» ¿µ»óÁø´Ü¿¡ ÅëÇÕÇÏ¿© µ¿¸Æ·ù °ËÃâ, À§Çèµµ ºÐ·ù, ¼ö¼ú °èȹÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3D ÇÁ¸°ÆÃ ±â¼úÀ» ÅëÇØ ȯÀÚº° ÇØºÎÇÐ ¸ðµ¨À» Á¦ÀÛÇÒ ¼ö ÀÖ¾î ¿Ü°úÀǻ簡 º¸´Ù Á¤¹ÐÇÏ°Ô °³ÀÔÀ» °èȹÇÏ°í ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸ñÀûÀ» ´Þ¼ºÇÏ¸é ¼­¼­È÷ ¿ëÇØµÇ´Â »ýü Èí¼ö¼º ½ºÅÙÆ®ÀÇ µµÀÔÀº µ¿¸Æ·ù °ü¸®ÀÇ ¶Ç ´Ù¸¥ ȹ±âÀûÀÎ ¹ßÀüÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¹ÙÀÌ¿À ¼ÒÀç¿Í ¾à¹° ¿ëÃâ ½ºÅÙÆ®¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸µµ Ç÷°ü Ä¡À¯¸¦ °³¼±ÇÏ°í ³»¸· ´©Ãâ°ú °°Àº ÇÕº´Áõ À§ÇèÀ» °¨¼Ò½ÃÄÑ µ¿¸Æ·ù Ä¡·áÀÇ ÁøÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀÌ Ä¡·áÀÇ Àü¸ÁÀ» °è¼Ó Çü¼ºÇϰí ÀÖ´Â °¡¿îµ¥, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Á¤¹Ð Ä¡·á Àü·«ÀÌ ÀÌ ÁúȯÀÇ °ü¸®¿¡¼­ Áß¿äÇÑ Æ®·»µå·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

´ëµ¿¸Æ·ù Ä¡·á ¼ö¿ä¸¦ °ßÀÎÇÏ´Â ½ÃÀå µ¿ÇâÀº?

¼¼°èÀûÀ¸·Î ´ëµ¿¸Æ·ù À¯º´·ü Áõ°¡´Â ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü°ú ÇÔ²² Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ½ÃÀåÀ» Çü¼ºÇÏ´Â °¡Àå µÎµå·¯Áø Æ®·»µå Áß Çϳª´Â ÃÖ¼Òħ½ÀÀû Ä¡·á·ÎÀÇ ÀüȯÀ¸·Î, EVAR°ú TEVAR´Â °³º¹¼ö¼ú¿¡ ºñÇØ À§ÇèÀÌ Àû°í ȸº¹ÀÌ »¡¶ó Ç¥ÁØ Ä¡·á¹ýÀ¸·Î ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ µîÀåÀ¸·Î º¸´Ù È¿°úÀûÀÎ ¼ö¼ú ÈÄ °ü¸®¿Í Àå±âÀûÀÎ µ¿¸Æ·ù ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ® ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀ» ³·Ãâ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿þ¾î·¯ºí ½ÉÇ÷°ü°è ¸ð´ÏÅ͸µ ±â±â ¹× AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®ÀÇ µµÀÔÀÌ È®´ëµÇ¸é¼­ µ¿¸Æ·ù ÁøÇàÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾î °íÀ§Ç豺 ȯÀÚ °ü¸®°¡ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² FDA¿Í À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦ ±â°üÀº »õ·Î¿î µ¿¸Æ·ù Ä¡·á ÀåÄ¡ÀÇ ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­ÇÏ¿© Â÷¼¼´ë ½ºÅÙÆ® ¹× ÀÌ½ÄÆíÀÇ ½Å¼ÓÇÑ ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹, ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­´Â ½ÉÇ÷°ü Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, µ¿¸Æ·ù °ËÁø ÇÁ·Î±×·¥ ¹× ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á±â±â Á¦Á¶¾÷ü, ¿¬±¸±â°ü, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·ÂÀÌ °­È­µÇ¸é¼­ Ä¡·áÀÇ Çõ½ÅÀ» ÃËÁøÇÏ°í º¸´Ù È¿À²ÀûÀ̰í ȯÀÚ Áß½ÉÀÇ ¼Ö·ç¼ÇÀ¸·Î ³ª¾Æ°¥ ¼ö ÀÖ´Â ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù.

´ëµ¿¸Æ·ù ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

´ëµ¿¸Æ·ù ½ÃÀåÀÇ ¼ºÀåÀº ½ºÅÙÆ® ÀÌ½Ä ¹× ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ ±â¼ú ¹ßÀü, ÀÎ½Ä °³¼± ¹× °ËÁø ÇÁ·Î±×·¥, Àü ¼¼°è ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ã Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. EVAR ¹× TEVAR ½Ã¼úÀº ¼ö¼ú À§ÇèÀ» ÁÙÀ̰í ȯÀÚÀÇ È¸º¹À» °³¼±ÇÏ´Â µ¥ ÀÖ¾î ÀÔÁõµÈ ÀåÁ¡¿¡ ÈûÀÔ¾î ½ÃÀå È®´ë¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ¿µ»ó Áø´Ü°ú ¿¹Ãø ºÐ¼®ÀÇ ÅëÇÕÀº Á¶±â ¹ß°ß°ú Ä¡·á °èȹÀ» °­È­ÇÏ¿© ´õ ³ªÀº ÀÓ»ó °á°ú¸¦ À̲ø¾î³»°í ÀÖ½À´Ï´Ù. ȯÀÚº° ¸ÂÃãÇü ½ºÅÙÆ® ±×¶óÇÁÆ®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÀÇ·á±â±â Á¦Á¶ÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, 3D ÇÁ¸°ÆÃ°ú ÷´Ü »ýü Àç·á°¡ Á¦Ç° °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ¿µ»ó ±â¼úÀ» °®Ãá ÇÏÀ̺긮µå ¼ö¼ú½ÇÀÇ Á¸Àç°¨ÀÌ Ä¿Áö¸é¼­ º¹ÀâÇÑ ¼ö¼úÀÌ º¸´Ù Á¤È®ÇÏ°í ¾ÈÀüÇÏ°Ô ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡Ä¡ ±â¹Ý ÀÇ·á¿Í ºñ¿ë È¿À²ÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ¿ø°Ý ¸ð´ÏÅ͸µ ¹× AI ±â¹Ý À§Çè Æò°¡ µµ±¸¿Í °°Àº Àå±âÀûÀÎ µ¿¸Æ·ù ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎ Áõ°¡¿Í Àα¸ÀÇ °í·ÉÈ­µµ ´ëµ¿¸Æ·ù ¹ß»ý·üÀ» ³ôÀÌ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ¾î ¿¹¹æ, Áø´Ü, Ä¡·áÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ±â¼ú Çõ½Å, ±ÔÁ¦ »óȲ, ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ À¶ÇյǸ鼭 ¼¼°è ½ÃÀå »óȲÀº Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(ÈäºÎ ´ëµ¿¸Æ·ù, º¹ºÎ ´ëµ¿¸Æ·ù);Ä¡·á(°üÇ÷Àû ¼ö¼ú ¼öº¹, Ç÷°ü³» µ¿¸Æ·ù ¼öº¹);Á¦Ç°(½ºÅÙÆ® ±×·¡ÇÁÆ®, Ä«Å×ÅÍ);ÃÖÁ¾ »ç¿ë(º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Ŭ¸®´Ð)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Aortic Aneurysm Market to Reach US$10.1 Billion by 2030

The global market for Aortic Aneurysm estimated at US$5.6 Billion in the year 2024, is expected to reach US$10.1 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2024-2030. Thoracic Aortic Aneurysm, one of the segments analyzed in the report, is expected to record a 11.7% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Abdominal Aortic Aneurysm segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 14.4% CAGR

The Aortic Aneurysm market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Aortic Aneurysm Market - Key Trends & Drivers Summarized

Why Is Aortic Aneurysm a Critical Cardiovascular Concern?

Aortic aneurysm is a life-threatening vascular condition characterized by the abnormal dilation or bulging of the aorta, the body's largest blood vessel. If left untreated, an aortic aneurysm can rupture, leading to severe internal bleeding and a high risk of mortality. The condition is primarily classified into two types: abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA), with AAA being more prevalent, especially among aging populations. Factors such as hypertension, smoking, high cholesterol, and genetic predisposition contribute significantly to the development of aortic aneurysms. The rise in sedentary lifestyles, obesity, and diabetes is further exacerbating the prevalence of aortic aneurysms globally. Advancements in diagnostic imaging, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), and ultrasound, have significantly improved early detection rates, allowing for timely intervention. However, the asymptomatic nature of the condition in its early stages makes screening programs crucial in high-risk demographics. Governments and healthcare organizations are increasingly focusing on awareness campaigns and routine screening for at-risk individuals, particularly males over 65 and individuals with a family history of aneurysms. The increasing burden of cardiovascular diseases (CVDs) has placed aortic aneurysm management at the forefront of modern cardiology, necessitating continued innovation in early detection, monitoring, and treatment.

How Are Technological Advancements Transforming Aortic Aneurysm Treatment?

Innovations in medical technology have revolutionized the diagnosis, monitoring, and treatment of aortic aneurysms, leading to better patient outcomes and reduced mortality rates. One of the most significant advancements in recent years has been the widespread adoption of endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR) techniques, which have largely replaced traditional open surgical procedures. These minimally invasive procedures involve the placement of stent grafts inside the aorta to reinforce weakened vessel walls, significantly reducing recovery time, hospital stays, and post-operative complications. In addition to procedural innovations, the integration of artificial intelligence (AI) and machine learning (ML) in imaging diagnostics is enhancing the precision and efficiency of aneurysm detection, risk stratification, and surgical planning. Furthermore, 3D printing technology is enabling the creation of patient-specific anatomical models, allowing surgeons to plan and customize interventions with greater accuracy. The introduction of bioresorbable stents, which gradually dissolve after serving their purpose, represents another breakthrough in aneurysm management. Continuous research into next-generation biomaterials and drug-eluting stents is also driving the evolution of aneurysm treatment by improving vascular healing and reducing the risk of complications such as endoleaks. As technological advancements continue to shape the landscape of aortic aneurysm care, personalized medicine and precision treatment strategies are emerging as key trends in the management of this condition.

What Market Trends Are Driving the Demand for Aortic Aneurysm Treatments?

The increasing global prevalence of aortic aneurysms, coupled with advancements in healthcare infrastructure, is driving a significant rise in demand for innovative treatment solutions. One of the most prominent trends shaping the market is the shift toward minimally invasive interventions, with EVAR and TEVAR gaining widespread acceptance as the standard of care due to their lower risk profiles and faster recovery times compared to open surgery. Additionally, the rise of telemedicine and remote monitoring solutions is enabling more effective post-operative care and long-term aneurysm surveillance, reducing the likelihood of complications. The growing adoption of wearable cardiovascular monitoring devices and AI-powered predictive analytics is further improving the management of high-risk patients by allowing for early detection of aneurysm progression. In parallel, regulatory bodies such as the FDA and the European Medicines Agency (EMA) are streamlining approval processes for novel aneurysm repair devices, facilitating faster market entry for next-generation stents and grafts. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing increased investments in cardiovascular care, leading to greater accessibility to aneurysm screening programs and advanced treatment modalities. Additionally, the growing collaboration between medical device manufacturers, research institutions, and healthcare providers is fostering innovation in aortic aneurysm treatment, paving the way for more efficient, patient-centered solutions.

What Are the Key Growth Drivers Fueling the Aortic Aneurysm Market?

The growth in the aortic aneurysm market is driven by several factors, including technological advancements in stent grafts and minimally invasive procedures, increasing awareness and screening programs, and the rising global burden of cardiovascular diseases. The expanding adoption of EVAR and TEVAR procedures, fueled by their proven benefits in reducing surgical risks and improving patient recovery, is significantly contributing to market expansion. Additionally, the integration of AI-driven diagnostic imaging and predictive analytics is enhancing early detection and treatment planning, leading to better clinical outcomes. The growing demand for patient-specific, customized stent grafts is driving innovation in medical device manufacturing, with 3D printing and advanced biomaterials playing a crucial role in product development. The increasing presence of hybrid operating rooms equipped with cutting-edge imaging technologies is further enabling complex aortic aneurysm procedures to be performed with greater precision and safety. Furthermore, the rising focus on value-based healthcare and cost-effective treatment options is prompting healthcare providers to invest in long-term aneurysm surveillance solutions, including remote monitoring and AI-powered risk assessment tools. The increasing prevalence of lifestyle-related risk factors, coupled with an aging population, is also contributing to a higher incidence of aortic aneurysms, reinforcing the need for continuous advancements in prevention, diagnosis, and treatment. As the market continues to evolve, the convergence of technological innovation, regulatory support, and patient-centered care is expected to drive sustained growth in the global aortic aneurysm treatment landscape.

SCOPE OF STUDY:

The report analyzes the Aortic Aneurysm market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Thoracic Aortic Aneurysm, Abdominal Aortic Aneurysm); Treatment (Open Surgical Repair, Endovascular Aneurysm Repair); Product (Stent Grafts, Catheters); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â